1. Home
  2. CGEM vs ASIC Comparison

CGEM vs ASIC Comparison

Compare CGEM & ASIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cullinan Oncology Inc.

CGEM

Cullinan Oncology Inc.

N/A

Current Price

$22.94

Market Cap

1.4B

Sector

Health Care

ML Signal

N/A

ASIC

Ategrity Specialty Insurance Company Holdings

HOLD

Current Price

$26.65

Market Cap

1.1B

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
CGEM
ASIC
Founded
2016
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Property-Casualty Insurers
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
1.4B
1.1B
IPO Year
2020
2025

Fundamental Metrics

Financial Performance
Metric
CGEM
ASIC
Price
$22.94
$26.65
Analyst Decision
Strong Buy
Buy
Analyst Count
8
4
Target Price
$30.13
$26.75
AVG Volume (30 Days)
667.8K
51.2K
Earning Date
05-11-2026
04-29-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
23.44
EPS
N/A
1.18
Revenue
N/A
$424,339,000.00
Revenue This Year
N/A
$34.21
Revenue Next Year
$5.20
$34.65
P/E Ratio
N/A
$22.80
Revenue Growth
N/A
23.41
52 Week Low
$5.68
$16.35
52 Week High
$23.06
$26.93

Technical Indicators

Market Signals
Indicator
CGEM
ASIC
Relative Strength Index (RSI) 70.67 62.81
Support Level $16.40 $18.42
Resistance Level N/A N/A
Average True Range (ATR) 1.20 0.86
MACD 0.29 0.16
Stochastic Oscillator 91.69 87.10

Price Performance

Historical Comparison
CGEM
ASIC

About CGEM Cullinan Oncology Inc.

Cullinan Therapeutics Inc is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer. Its development pipeline comprises the following drug candidates: CLN-978, a CD19xCD3 bispecific T cell engager that is being developed for autoimmune diseases; CLN-049, a FLT3xCD3 bispecific T cell engager being evaluated in an ongoing clinical trial in patients with relapsed/refractory acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); Velinotamig, a BCMAxCD3 bispecific T cell engager being developed to counter autoimmune diseases; and Zipalertinib, being developed as a treatment for non-small cell lung cancer. Additionally, the company is developing several preclinical programs in autoimmune diseases and oncology.

About ASIC Ategrity Specialty Insurance Company Holdings

Ategrity Specialty Insurance Co Holdings is a specialty property and casualty insurance holding company focused on the excess and surplus market for small to medium-sized businesses (SMBs) across the United States. Operating through its subsidiaries, the company underwrites small and medium-sized commercial risks across selected industry verticals, including Retail, Real Estate, Hospitality, and Construction. Its operating model uses a technology-driven method to standardize, simplify, and, where appropriate, automate these transactions. The group distributes its products through licensed surplus lines brokers and wholesale agents.

Share on Social Networks: